找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Top Articles in Primary Care; John Russell,Neil S. Skolnik Book 2023 The Editor(s) (if applicable) and The Author(s), under exclusive lice

[复制链接]
楼主: 正当理由
发表于 2025-3-25 05:54:48 | 显示全部楼层
发表于 2025-3-25 09:46:22 | 显示全部楼层
the chronological order of publication. Each article reviewed includes a succinct overview of methodology and the results, followed by a discussion that puts the results into clinical context.  All articles ar978-3-031-25619-6978-3-031-25620-2
发表于 2025-3-25 12:17:53 | 显示全部楼层
发表于 2025-3-25 19:09:57 | 显示全部楼层
发表于 2025-3-25 20:35:32 | 显示全部楼层
发表于 2025-3-26 03:30:34 | 显示全部楼层
Thrombolysis in Acute Strokes (ECASS-II)-1998ith a clot dissolver called tissue plasminogen activator (TPA) [1]. The ECASS II trial was one of the first trials to review the safety and efficacy of alteplase (recombinant TPA) which to this day is still one of the first line therapies for ischemic CVA.
发表于 2025-3-26 05:20:51 | 显示全部楼层
发表于 2025-3-26 11:18:58 | 显示全部楼层
发表于 2025-3-26 12:44:27 | 显示全部楼层
发表于 2025-3-26 19:21:17 | 显示全部楼层
Empagliflozin in Diastolic Heart Failure (EMPEROR)-2021unction, among other pathophysiologic abnormalities [1]. Multiple trials in patients with HFpEF have failed to reach their primary endpoints. The EMPEROR-PRESERVED trial is the first trial to have reach its primary outcome in patients with HFpEF.
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-11 17:57
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表